{"id":"NCT01625338","sponsor":"Gilead Sciences","briefTitle":"Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies","officialTitle":"An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2014-10","completion":"2014-12","firstPosted":"2012-06-21","resultsPosted":"2015-11-09","lastUpdate":"2015-11-09"},"enrollment":534,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"SOF","otherNames":["SovaldiÂ®","GS-7977","PSI-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]},{"type":"DRUG","name":"Peg-IFN","otherNames":[]}],"arms":[{"label":"SOF+RBV 12 Weeks","type":"EXPERIMENTAL"},{"label":"SOF+RBV 24 Weeks","type":"EXPERIMENTAL"},{"label":"SOF+RBV+Peg-IFN 12 Weeks","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF+RBV 12 Weeks","deltaMin":71.9,"sd":null},{"arm":"SOF+RBV 24 Weeks","deltaMin":77.5,"sd":null},{"arm":"SOF+RBV+Peg-IFN 12 Weeks","deltaMin":82.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":175,"countries":["United States","Australia","Austria","Canada","Czechia","Estonia","France","Germany","Italy","Netherlands","New Zealand","Poland","Puerto Rico","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":114},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Pruritus"]}}